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Abstract
IMPORTANCE Patients with nonvalvular atrial fibrillation at risk of stroke should receive oral
anticoagulants (OAC). However, approximately 1 in 8 patients in the Global Anticoagulant Registry in
the Field (GARFIELD-AF) registry are treatedwith antiplatelet (AP) drugs in addition toOAC, with or
without documented vascular disease or other indications for AP therapy.
OBJECTIVE To investigate baseline characteristics and outcomes of patients who were prescribed
OAC plus AP therapy vs OAC alone.
DESIGN, SETTING, AND PARTICIPANTS Prospective cohort study of the GARFIELD-AF registry, an
international, multicenter, observational study of adults aged 18 years and older with recently
diagnosed nonvalvular atrial fibrillation and at least 1 risk factor for stroke enrolled between March
2010 and August 2016. Data were extracted for analysis in October 2017 and analyzed from April
2018 to June 2019.
EXPOSURE Participants received either OAC plus AP or OAC alone.
MAINOUTCOMES ANDMEASURES Clinical outcomes weremeasured over 3 and 12months.
Outcomes were adjusted for 40 covariates, including baseline conditions andmedications.
RESULTS A total of 24 436 patients (13 438 [55.0%]male; median [interquartile range] age, 71
[64-78] years) were analyzed. Among eligible patients, those receiving OAC plus AP therapy had a
greater prevalence of cardiovascular indications for AP, including acute coronary syndromes (22.0%
vs 4.3%), coronary artery disease (39.1% vs 9.8%), and carotid occlusive disease (4.8% vs 2.0%).
Over 1 year, patients treated with OAC plus AP had significantly higher incidence rates of stroke
(adjusted hazard ratio [aHR], 1.49; 95% CI, 1.01-2.20) and any bleeding event (aHR, 1.41; 95% CI, 1.17-
1.70) than those treatedwith OAC alone. These patients did not show evidence of reduced all-cause
mortality (aHR, 1.22; 95%CI, 0.98-1.51). Risk of acute coronary syndromewas not reduced in patients
taking OAC plus AP compared with OAC alone (aHR, 1.16; 95% CI, 0.70-1.94). Patients treated with
OAC plus AP also had higher rates of all clinical outcomes than those treated with OAC alone over the
short term (3months).
CONCLUSIONS ANDRELEVANCE This study challenges the practice of coprescribing OAC plus AP
unless there is a clear indication for adding AP to OAC therapy in newly diagnosed atrial fibrillation.
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Key Points
Question What outcomes are
associated with combination therapy
using oral anticoagulants (OAC) plus
antiplatelet drugs in patients with newly
diagnosed atrial fibrillation?
Findings This cohort study of 24 436
patients with de novo atrial fibrillation
found that, after adjusting for baseline
characteristics and comedications,
patients treated with OAC plus
antiplatelet drugs had significantly
higher incidence rates of stroke and any
bleeding event than those receivingOAC
alone. Use of OAC plus antiplatelet drugs
was not associated with reduced risk of
experiencing acute coronary
syndromes.
Meaning These findings suggest that
patients with atrial fibrillation treated
with OAC plus antiplatelet drugs may
have significantly higher risk of stroke
and bleeding compared with those
receiving OAC alone.
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Introduction
Atrial fibrillation (AF) occurs when structural remodeling and/or electrophysiological abnormalities
(eg, myocarditis or fibrosis) caused by diverse pathophysiological mechanisms (eg, hypertension or
heart failure) alter atrial tissue to promote abnormal pulse wave generation and/or propagation,
leading to atrial tachyarrhythmias.1,2 Both AF and the underlying abnormal atrial tissue predispose
affected individuals to thrombus formation in the left atrium or left atrial appendage, and this can
embolize to the brain and other sites. Guidelines1,2 recommend that patients with nonvalvular AF and
CHA2DS2-VASc (cardiac failure, hypertension, age >75 years [2 points], diabetes, stroke, transient
ischemic attack, or thromboembolism [2 points]–vascular disease, age >60 years, sex category
female)3,4 risk stratification score of 2 or greater (not counting sex) should receive oral
anticoagulation (OAC; vitamin K antagonist [VKA] or non-VKA OACs [NOACs]) as stroke prophylaxis
regardless of symptoms; in patients with CHA2DS2-VASc score of 1, OAC may be considered.
Although antiplatelet (AP) agents are not advocated for stroke prophylaxis in AF, it is known that
some patients are coprescribed these drugs with OAC.5-8
Patients with new-onset AFmay have comorbid cardiovascular disease (CVD) requiring therapy
with OAC in combination with AP.8 Potential benefits of AP drugs in patients with CVDmay be due
to their favorable effects on inhibiting arterial thrombosis.9,10 Antiplatelet drugs may be given in
combination with OAC in patients with AF after percutaneous coronary intervention, to prevent
stent thrombosis, or after acute coronary syndromes (ACS).1,2 In patients with AF who require
stenting, guidelines recommend concurrent AP plus OAC for up to 1 year and, in those at risk for
stroke, OAC alone thereafter.11,12
In the large observational Global Anticoagulant Registry in the Field–Atrial Fibrillation
(GARFIELD-AF) study,5 approximately 1 in 8 patients with AF at risk for stroke received AP therapy
concomitantly with OAC, irrespective of whether they had a confirmed indication for AP. Because the
balance of risk vs benefit with combination therapy using OAC plus AP is not well defined, the
present study investigated baseline characteristics and outcomes of patients who were newly
prescribed OAC plus AP therapy at the time of diagnosis of AF, using data from GARFIELD-AF.
Methods
StudyDesign and Participants
The GARFIELD-AF study design andmain findings have been reported previously.5,13 The registry is a
prospective, multicenter, observational study of adults aged 18 years and older with recently
diagnosed nonvalvular AF and at least 1 risk factor for stroke. Patients were recruited from a range of
representative care settings in each country betweenDecember 2009 andOctober 2017. No specific
treatments, tests, or procedures were mandated by the study protocol. Decisions to initiate,
continue, or change treatment were solely at the discretion of treating physicians. Patients with a
transient reversible cause of AF and those for whom follow-up was not envisaged or possible were
excluded.2
Independent ethics committee and hospital-based institutional review board approvals were
obtained for the GARFIELD-AF study, including all subsequent analyses of the data. The registry was
conducted in accordance with the principles of the Declaration of Helsinki,14 local regulatory
requirements, and the International Conference on Harmonisation–Good Pharmacoepidemiological
and Clinical Practice guidelines.Written informed consentwas obtained from all study participants.
This study followed the Strengthening theReporting ofObservational Studies in Epidemiology (STROBE)
reporting guideline.
Data Capture
In this prospective observational study, outcomes were captured by electronic case report forms.
Submitted data were examined for completeness and accuracy by the coordinating center
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(Thrombosis Research Institute, London, United Kingdom), and data queries were sent to study sites.
An audit and quality control programwas implemented that included source documentation (20%
of all electronic case report forms weremonitored against source records).15
Baseline characteristics collected at study entry includedmedical history, care setting, type of
AF, date and method of diagnosis of AF, symptoms, antithrombotic treatment (VKAs, NOACs, and
AP), as well as all cardiovascular drugs. Race was classified by the investigator in agreement with the
patient.13 Vascular disease included coronary artery disease (CAD) with a history of ACS and/or
peripheral artery disease. Chronic kidney disease was classified according to National Kidney
Foundation guidelines into moderate to severe (stages 3-5), mild (stages 1 and 2), or none. Data on
components of the CHA2DS2-VASc risk stratification scheme were collected and calculated
retrospectively since patients’ inclusion in the registry was decided by physicians’ clinical judgment.
Collection of follow-up data occurred at 4-month intervals up to 24 months. Data for the present
investigation were extracted from the study database in October 2017 and analyzed from April 2018
to June 2019.
In the present analysis, clinical outcomes and bleeding risk were investigated and compared in
patients with de novo AF who received either OAC plus AP or OAC alone over 3 and 12months.
Statistical Analysis
Patients who were prescribed AP drugs, defined as aspirin or P2Y12-type ADP receptor inhibitors in
combination with OAC were compared with those who did not receive concomitant AP therapy. To
reduce risk of bias due to patient selection, patients who had previously takenOACs or AP drugswere
excluded from this analysis, as were those prescribed VKA and a NOAC. Subgroup analyses were
performed in patients classified as having low and high risk for AF-related stroke (defined as
CHA2DS2-VASc score <2 and2, respectively).
An intent-to-treat analysis was calculated using Cox proportional hazards regression to estimate
multivariate adjusted hazard ratios (aHR) and 95% confidence intervals for the study end points of
all-cause mortality, myocardial infarction (MI) or ACS, stroke, stroke or systemic embolism, any
bleeding, major bleeding, major bleeding and hemorrhagic stroke, andmajor or nonmajor clinically
relevant bleeding (see study design article13 for definitions of these events). Models were adjusted
for 40 covariates (eTable 1 in the Supplement) reflecting demographic and clinical characteristics,
medical history, and concomitant medication at registry entry. The covariates included all
documented vascular indications for AP therapy. As a falsification analysis, the same approach was
used to investigate the influence of supplemental AP therapy on an implausible end point such as
death unrelated to cardiovascular disease. For each adverse outcome analyzed, patients were
censored on first occurrence of that event, loss to follow-up, death, or reaching 90 days of follow-up
for 3-month analyses and 365 days for 12-month analyses. Additionally, a propensity score model
including the same set of covariates was developed and patients treated with AP drugs were
matched 1:1 to patients not treatedwith AP drugs to create balanced cohorts, in which Cox regression
was used to estimate HRs and 95% confidence intervals. Patients withmissing values were included
in the analysis.
A supplementary as-treated analysis was performed for all study end points using Cox
proportional hazard regression to estimate multivariate adjusted HRs and 95% confidence intervals
in the full analysis population and in the propensity score–matched cohorts that we have described.
Patients were censored on occurrence of any outcome, loss to follow-up, death, discontinuation of
therapy, or interruption of index therapy plus a 7-day risk window, addition or change of the index AP
regimen, or reaching 365 days of follow-up.
An α of .05 (2-tailed) was used for statistical significance. All analyses were conducted using
Aetion Evidence Platform version 3.13 (Aetion Inc).
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Results
Baseline Patient Characteristics
In total, 57 276 patients were enrolled in GARFIELD-AF between December 2009 and October 2017.
After all inclusion and exclusion criteria were applied, the final number of eligible patients newly
treated with OAC plus AP or OAC alone at registry entry was 24 436 (13 438 [55.0%]male; median
[interquartile range] age, 71 [64-78] years) (Figure 1). Of these, 3059 patients (12.5%) composed the
OAC plus AP group, and 21 377 (87.2%) composed the OAC alone group. Both patients who received
OAC plus AP and those who received OAC alone had a median age of 71 years. The majority of
patients (84.4%) had amoderate to high risk of stroke (CHA2DS2-VASc score2); in the overall
population, the median (interquartile range) CHA2DS2-VASc score was 3 (2-4) (Table).
Compared with patients receiving OAC alone, those who received OAC plus AP therapy had a
greater prevalence of cardiovascular indications for AP, including ACS (22.0% vs 4.3%), CAD (39.1%
vs 9.8%), and carotid occlusive disease (4.8% vs 2.0%). These patients also had a higher prevalence
of cardiovascular conditions such as congestive heart failure (25.2% vs 16.8%), history of
Figure 1. Patients’ Disposition in the Study
57 276 Patients assessed for eligibility
20 110 Ineligible
24 436 Total eligible analysis population
3059 Treated with OAC + AP 21 377 Treated with OAC alone
12 730 Excluded
37 166 Treated with OAC at study entry
Table. Clinical Characteristics of PatientsWith Atrial Fibrillation TreatedWith OAC Plus AP or OAC Alone
for Stroke Prophylaxis
Parameter OAC Plus AP (n = 3059) OAC Alone (n = 21 377)
Male, No. (%) 1925 (62.9) 11 513 (53.9)
Age, mean (SD), y 69.8 (10.6) 70.3 (11.0)
Body mass index, mean (SD)a 28.2 (5.6) 27.9 (5.8)
Blood pressure, systolic/diastolic, mean 132.9/79.7 134.6/80.5
Pulse rate, mean (SD), beats/min 90.9 (26.9) 91.4 (26.7)
Left ventricular ejection fraction, mean (SD), % 52.8 (13.8) 56.7 (12.4)
CHA2DS2-VASc score, median (IQR) 3 (2-4) 3 (2-4)
Medical history, No. (%)
Congestive heart failure 770 (25.2) 3587 (16.8)
Coronary artery disease 1195 (39.1) 2100 (9.8)
Acute coronary syndrome 673 (22.0) 926 (4.3)
Carotid occlusive disease 146 (4.8) 437 (2.0)
Deep vein thrombosis or pulmonary embolism 106 (3.5) 609 (2.8)
Stroke or transient ischemic attack 503 (16.4) 1902 (8.9)
Bleeding 84 (2.7) 346 (1.6)
Hypertension 2468 (80.7) 16 290 (76.2)
Hypercholesterolemia 1501 (49.1) 7771 (36.4)
Diabetes, type 1 or 2 923 (30.2) 4245 (19.9)
Chronic kidney disease, moderate to severe 406 (13.3) 2099 (9.8)
Abbreviations: AP, antiplatelet; CHA2DS2-VASc, cardiac
failure, hypertension, age greater than 75 years (2
points), diabetes, stroke, transient ischemic attack, or
thromboembolism (2 points)–vascular disease, age
greater than 60 years, sex category female; IQR,
interquartile range; OAC, oral anticoagulant.
a Calculated as weight in kilograms divided by height
in meters squared.
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hypertension (80.7% vs 76.2%), history of hypercholesterolemia (49.1% vs 36.4%), and history of
bleeding (2.7% vs 1.6%) as well as severe renal disease (13.3% vs 9.8%) and diabetes (30.2% vs
19.9%). A higher proportion of patients receiving OAC plus AP weremale (Table).
Among 20687 patients at high risk of stroke (CHA2DS2-VASc score2), 2735 (13.2%) received
OAC plus AP therapy. This subpopulation had a higher prevalence of indications for AP, cardiovascular
conditions (except congestive heart failure), severe renal disease, and diabetes and higher likelihood
of receiving cardiovascular medications than their counterparts receiving OAC alone. Within this
high-risk subpopulation, median (interquartile range) CHA2DS2-VASc score for those prescribed OAC
plus AP and OAC alone was 4 (3-4) and 3 (2-4), respectively (eTable 2 in the Supplement).
Clinical Outcomes at 12Months
Unadjusted and adjusted HRs for outcome events over 12 months are displayed in Figure 2. After
adjustment for 40 covariates, including baseline medications, patients treated with OAC plus AP had
significantly higher incidence rates of stroke (aHR, 1.49; 95% CI, 1.01-2.20) and any bleeding event
(aHR, 1.41; 95% CI, 1.17-1.70) as well as composite end points death or stroke (aHR, 1.27; 95% CI, 1.05-
1.55) and death, stroke, or major bleeding (aHR, 1.32; 95%CI, 1.10-1.59) than those treatedwith OAC
alone. Moreover, patients prescribed OAC plus AP did not show evidence of reduced all-cause
mortality (aHR, 1.22; 95% CI, 0.98-1.51), stroke and/or systemic embolism (aHR, 1.32; 95% CI,
0.90-1.93), andmajor bleeding events including hemorrhagic stroke (aHR, 1.40; 95% CI, 0.93-2.11).
Risk of ACS was not reduced in patients taking OAC plus AP compared with OAC alone (aHR, 1.16;
95% CI, 0.70-1.94). Hazard ratios generated from the propensity score model were similar for each
Figure 2. Relative Risk (Hazard Ratios [HRs], Unadjusted and Adjusted) for Study Outcomes in Patients
With Newly Diagnosed Atrial Fibrillation TreatedWith Oral Anticoagulants (OAC) Plus Antiplatelet Drugs (AP)
or OAC Alone (Reference) Over 12Months (Intent-to-Treat Analyses)
0.5 51
HR (95% CI)
No. of Events
OAC
+ AP
OAC
Alone
All-cause mortality 125 561 1.22 (0.98-1.51)
HR
(95% CI)
Adjusted
Unadjusted
MI or ACS 26 80 1.16 (0.70-1.94)
Stroke 39 160 1.49 (1.01-2.20)
Stroke or SE 40 181 1.32 (0.90-1.93)
Any bleeding event 170 750 1.41 (1.17-1.70)
Major bleeding event 31 138 1.37 (0.89-2.12)
Major or NMCR bleeding event 76 335 1.45 (1.10-1.92)
Major bleeding event
(including hemorrhagic stroke)
35 150 1.40 (0.93-2.11)
Adjusted
Unadjusted
Adjusted
Unadjusted
Adjusted
Unadjusted
Adjusted
Unadjusted
Adjusted
Unadjusted
Adjusted
Unadjusted
Adjusted
Unadjusted
Hazard ratios were adjusted for 40 covariates as
shown in eTable 1 in the Supplement. AP indicates
antiplatelet drugs; and OAC, oral anticoagulants. ACS
indicates acute coronary syndromes; MI, myocardial
infarction; NMCR, nonmajor, clinically relevant; and SE,
systemic embolism.
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outcome, although precision was slightly reduced owing to smaller sample size after matching 1:1
(results not shown).
Within the subpopulation of patients at high risk for stroke, the aHRs and HRs generated from
the propensity score model were similar to those seen in the overall population for all outcomes (eg,
stroke: aHR 1.55; 95% CI, 1.04-2.30; any bleeding event: aHR, 1.42; 95% CI, 1.17-1.72; major and
nonmajor clinically relevant bleeding: aHR, 1.50; 95% CI, 1.13-1.99; death or stroke: aHR, 1.27; 95% CI,
1.04-1.56; death, stroke, or major bleeding: aHR, 1.33; 95% CI, 1.10-1.60). No reductions in risk of
other clinical outcomes with OAC plus AP vs OAC alone were noted, including ACS (eFigure 1 in the
Supplement).
Clinical Outcomes at 3Months
Patients treated with OAC plus AP at registry entry had numerically higher rates of all clinical
outcomes than those treated with OAC alone over 3 months (Figure 3). However, only any bleeding
(aHR, 1.54; 95% CI, 1.15-2.07), major and nonmajor clinically relevant bleeding (aHR, 1.86; 95% CI,
1.20-2.88), and death, stroke, or major bleeding (aHR, 1.48; 95% CI, 1.07-2.06) exhibited statistically
significant increases. Similar patterns were seen among the subgroup of patients at high risk for
stroke at 3 months of follow-up (eFigure 2 in the Supplement).
As-TreatedAnalyses
As-treated analyses, in which patients were censored at the time of discontinuation or change of
initial treatment, resulted in similar findings to the primary intent-to-treat analyses (data not shown).
Figure 3. Relative Risk (Hazard Ratios [HRs], Unadjusted and Adjusted) for Study Outcomes in Patients
With Newly Diagnosed Atrial Fibrillation TreatedWith Oral Anticoagulants (OAC) Plus Antiplatelet Drugs (AP)
or OAC Alone (Reference) Over 3Months (Intent-to-Treat Analyses)
0.5 71
HR (95% CI)
No. of Events
OAC
+ AP
OAC
Alone
All-cause mortality 37 154 1.24 (0.82-1.88)
HR
(95% CI)
Adjusted
Unadjusted
MI or ACS 14 29 1.78 (0.82-3.86)
Stroke 13 50 1.65 (0.84-3.26)
Stroke or SE 13 53 1.57 (0.80-3.08)
Any bleeding event 72 276 1.54 (1.15-2.07)
Major bleeding event 13 41 1.95 (0.94-4.03)
Major or NMCR bleeding event 33 117 1.86 (1.20-2.88)
Major bleeding event
(including hemorrhagic stroke)
13 46 1.78 (0.88-3.62)
Adjusted
Unadjusted
Adjusted
Unadjusted
Adjusted
Unadjusted
Adjusted
Unadjusted
Adjusted
Unadjusted
Adjusted
Unadjusted
Adjusted
Unadjusted
Hazard ratios were adjusted for 40 covariates as
shown in eTable 1 in the Supplement. ACS indicates
acute coronary syndromes; MI, myocardial infarction;
NMCR, nonmajor, clinically relevant; and SE, systemic
embolism.
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Falsification Analysis
Among 2541 patients treated with OAC plus AP and 17 673 patients treated with OAC alone who died
from causes unrelated to cardiovascular disease over the first 12months, risk per 1000 patients was
estimated to be 9.45 and 11.32, respectively (aHR for event, 0.76; 95% CI, 0.48-1.22) (eTable 3 in the
Supplement).
Discussion
In this prospective registry of patients with newly diagnosed AF receiving anticoagulant therapy, the
majority (87.2%) was treated with OAC alone, whereas 1 in 8 individuals (12.5%) received OAC plus
AP. Patients prescribed OAC plus AP had a higher burden of cardiovascular indications for AP therapy
such as ACS, CAD, and carotid occlusive disease, as well as a range of cardiovascular conditions that
AP drugs are not known to ameliorate, including hypertension, diabetes (an independent risk factor
for MI and stroke16,17), and history of bleeding. During the observation period, patients treated with
OAC plus AP experienced a higher incidence of adverse outcomes such as stroke, bleeding, and death
than those treated with OAC alone over the longer term (12 months) and shorter term (3 months),
both before and after adjusting for baseline conditions and comedications. Moreover, patients
receiving OAC plus AP did not achieve lower risk of ACS vs patients who were prescribed OAC alone.
Reducing early risk is challenging because it is known that the rate of cardiovascular mortality is
highest during the first 1 month after diagnosis of AF.18
Patients presenting with AF andmoderate to high risk for AF-related stroke (CHA2DS2-VASc
score2)19,20 are usually offered anticoagulant therapy. In low-risk patients (CHA2DS2-VASc1),
neither OAC nor AP is recommended because the potential for causing bleeding as an adverse effect
could exceed the beneficial effects of preventing stroke. Conversely, in higher-risk patients,
preventing stroke is a treatment priority, albeit at a cost of some increase in risk of bleeding.
Antiplatelet drugs such as aspirin and clopidogrel, either alone or in combination (dual AP therapy),
have been demonstrated to be less efficacious than OACs at preventing stroke in patients with AF
and can cause similar or higher rates of bleeding.21-31 Therefore, AP drugs are not routinely
recommended for stroke prophylaxis in patients with AF.
Combining antithrombotic drugs increases their potential to cause bleeding. In a Danish registry
study of 82 854 patients with AFwith follow-up ofmore than 3 years, drug-induced nonfatal or fatal
bleeding was seen in 11.4%; the risk was lowest in patients who took aspirin or warfarin monotherapy,
slightly higher for clopidogrel, andmarkedly higher (more than 3-fold comparedwithwarfarin alone)
for dual warfarin plus clopidogrel and triple therapy usingwarfarin, aspirin, and clopidogrel.32 These
findings were confirmed in patients with AF receiving multiple antithrombotic drugs, including triple
therapy, followingMI or percutaneous coronary intervention.33,34 The same researchers
retrospectively studied patients with AF with coexisting stable CAD and found that risk of recurrent
coronary events or thromboembolism was the same for VKA plus aspirin or clopidogrel as for VKA
alone, whereas the risk for bleeding increased when either AP drug was given concurrently
with VKA.35
Hsu et al36 analyzed 200000 outpatients with AF at risk for stroke enrolled in the American
College of Cardiology’s Practice Innovation and Clinical Excellence (PINNACLE) registry and identified
factors associatedwith prescribing aspirin alone over OAC that included hypertension, dyslipidemia,
CAD, prior MI, angina, recent coronary artery bypass graft, and peripheral artery disease. Patients
prescribed OAC, on the other hand, were more oftenmale or had higher bodymass index, prior
stroke or transient ischemic attack, or heart failure.
Steinberg and colleagues6 looked at patterns of use and associated risks of coprescribing
antithrombotic drugs in a cohort of 10000 patients enrolled in the US-based Outcomes Registry for
Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) study. Patients receiving aspirin plus OAC
weremore likely to bemale (66%vs 53%; P < .0001) and hadmore comorbid illness, although 39%
did not have atherosclerotic disease. Major bleeding and bleeding hospitalizations were significantly
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greater (by approximately 50%) in patients receiving aspirin plus OAC than in those receiving OAC
alone. Overall rates of ischemic events were low. These researchers suggested that adding aspirin
therapy to OACmay not beworth the risk in AF, in particular in patients who do not have a convincing
indication for aspirin, such as manifest atherosclerosis.
Several clinical trials37-39 have investigated the efficacy and safety of add-on AP therapy in
patients with AF receiving OACs. In the Apixaban for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation (ARISTOTLE) study37 conducted in more than 18000 patients with AF at
risk of stroke, apixaban exerted comparable favorable effects on preventing stroke, systemic
embolism, andmortality and caused lessmajor bleeding thanwarfarin irrespective of whether aspirin
was concomitantly used, including in subgroups of patients with arterial disease. Comparable
findings were reported for the pivotal Effective Anticoagulation with Factor Xa Next Generation in
Atrial Fibrillation (ENGAGE-AF) study38 of edoxaban vs warfarin and Rivaroxaban Once Daily Oral
Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and
Embolism Trial in Atrial Fibrillation (ROCKET AF) trial39 of rivaroxaban vs warfarin in AF.
Strengths and Limitations
To our knowledge, GARFIELD-AF is the largest international prospective registry in AF with extensive
quality control measures providing reassurance for accuracy of results.5,13,15 Although the data were
adjusted for an extensive range of clinical and medical history variables known to influence
outcomes, differences between patients treated with either OAC plus AP or OAC alonemay be
subject to unmeasured confounders related to treatment selection by physicians. Indeed, although
we were able to analyze clinical scenarios significantly associated with likelihood of receiving
comedication with OAC plus AP, treating physicians’ actual reasons for adopting this strategy in
individual patients were not recorded. On the other hand, our falsification analysis suggests lack of
appreciable bias in this research. Patients included in the present analysis had not received prior OAC
or AP therapy.
Conclusions
This study suggests that patients with AF at risk for stroke who receive OAC do not require
supplemental AP therapy unless there are clear indications for these medications, such as
intercurrent ACS or as adjunct to percutaneous coronary intervention. However, this study shows
that approximately 1 in 8 patients who are not in this category do receive OAC plus AP. In this study,
patients receiving add-on AP therapy had more cardiovascular complications than those given OAC
alone, even after adjusting for all baseline risk factors and medications. These findings challenge the
clinical practice of combiningOAC and AP therapy for stroke prevention in patients with de novo AF.
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